Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 5:05PM CST
Pharmacyclics, Inc. (PCYC) announced that the FDA is expected to render a final opinion on the supplemental New Drug Application for Imbruvica for WM indication by Apr 17, 2015.
AGN: 210.12 (+0.95), JNJ: 104.59 (+0.31), ACT: 254.20 (-1.68), PCYC: 121.84 (+1.15)
Bristol-Myers Oncology Drug Opdivo Receives FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:45PM CST
Bristol-Myers Squibb Company announced that the FDA has cleared its intravenous human programmed death receptor-1 blocking antibody, Opdivo.
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), MRK: 57.46 (+0.25), BMY: 59.15 (-0.01)
After Yesterday's Decline of 1.05%, Allergan Offers Investors Better Value
Comtex SmarTrend(R) - Tue Dec 23, 3:55PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $207.23 to a high of $212.67. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $209.54 on volume of 2.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 210.12 (+0.95)
Keryx (KERX) Launches Renal Drug Auryxia in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:35PM CST
Keryx Biopharmaceuticals, Inc. (KERX) announced it has begun to ship Auryxia (ferric citrate) tablets to wholesalers in the U.S.
AGN: 210.12 (+0.95), SHPG: 209.29 (+0.07), SCMP: 13.75 (+0.44), KERX: 14.00 (+0.20)
Aerie: A Brilliant Future, Derisking In Progress, And The Making Of A Major Ophthalmic Pharmaceutical
Northern Fundamentals - at Seeking Alpha - Tue Dec 23, 11:45AM CST
AGN: 210.12 (+0.95), VRX: 140.33 (-0.22), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AERI: 29.49 (+1.23), NVS: 93.91 (+0.66)
SHAREHOLDER ALERT: Investors Who Sold Allergan, Inc. Common Stock Between February 25, 2014 and April 21, 2014 Are Encouraged to Contact Glancy Binkow & Goldberg LLP
Business Wire - Tue Dec 23, 11:32AM CST
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of persons who sold the common stock of Allergan, Inc. ("Allergan" or the "Company"
AGN: 210.12 (+0.95)
Actavis' Antibiotic a Step Closer to EU Nod, CHMP Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 4:51PM CST
Actavis' (ACT) antibiotic, Xydalba, which is already marketed in the U.S. under the trade name Dalvance, is a step closer to EU approval.
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)
AstraZeneca's Lynparza Cleared in U.S. for Ovarian Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 4:45PM CST
The FDA has cleared AstraZeneca's (AZN) Lynparza as a monotherapy for the maintenance treatment of adults suffering from advanced ovarian cancer.
AGN: 210.12 (+0.95), AZN: 70.44 (+0.26), AMGN: 160.67 (+3.15), ABBV: 66.21 (+1.86)
Roche to Acquire Austrian Biotechnology Company Dutalys - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:55PM CST
Roche (RHHBY) recently announced it has agreed to acquire a privately-held Austrian biotechnology company named Dutalys GmbH.
AGN: 210.12 (+0.95), BIIB: 340.89 (+5.13), ABBV: 66.21 (+1.86)
Novo Nordisk's Tresiba Favored by CHMP for Expanded Use - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 2:10PM CST
Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended Tresiba for expanded use.
AGN: 210.12 (+0.95), BIIB: 340.89 (+5.13), NVO: 43.80 (+1.08), ABBV: 66.21 (+1.86)
Shares of AGN Up 27.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Dec 22, 9:17AM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 3 months, Allergan has returned 27.52% as of today's recent price of $213.09.
AGN: 210.12 (+0.95)
Merck Up on OncoEthix Acquisition Deal, Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 4:20PM CST
Merck (MRK) acquired Swiss biotech privately held company, OncoEthix, and added a promising experimental early-stage candidate, OTX015, to its oncology portfolio.
AGN: 210.12 (+0.95), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), ABBV: 66.21 (+1.86)
AstraZeneca's Lynparza Approved in EU for Ovarian Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 3:48PM CST
AstraZeneca's (AZN) Lynparza was approved as a monotherapy for the maintenance treatment of adults suffering from ovarian cancer.
AGN: 210.12 (+0.95), CLVS: 54.58 (+0.43), AZN: 70.44 (+0.26), ABBV: 66.21 (+1.86)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)
The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?
Todd Campbell, The Motley Fool - Motley Fool - Fri Dec 19, 6:44AM CST
From Medicaid expansion to cancer drugs to minimally invasive treatment for heart disease, Industry Focus looks at the 10 top performers among large-cap healthcare stocks in 2014. There were some surprises on the list this year, with strong showings...
AGN: 210.12 (+0.95), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), JNJ: 104.59 (+0.31), VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), EW: 130.75 (+1.17), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07)
Acne Vulgaris - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/86w8nv/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Advancell - Allergan - AndroScience - AntiCancer - Ausio Pharmaceuticals - Biomar Microbial - Boehringer Ingelheim - Braintree Laboratories - Celtaxsys - Cosmo Pharmaceuticals - Cutanea Life Sciences - Delenex Therapeutics - Deltanoid Pharmaceuticals - Dermira - ELORAC - Ensoltek - Foamix - Galderma - GlaxoSmithKline - Kasiak Research - Maruho - OrigImm - Phosphagenics - Photocure - Provectus Biopharmaceuticals - RestorGenex Corporation - Thesan Pharmaceuticals - Toyama Chemical - Valeant Pharmaceuticals International - XBiotech USA - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/86...e_vulgaris
PVCT: 0.85 (-0.02), AGN: 210.12 (+0.95), GSK: 42.85 (+0.11), XOMA: 3.68 (+0.11), VRX.TO: 162.98 (-0.62)
AGN SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Involving Allergan, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 16, 2015 -- AGN
GlobeNewswire - Thu Dec 18, 4:48PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who sold Allergan, Inc. ("Allergan" or the "Company"
AGN: 210.12 (+0.95)
EQUITY ALERT: The Rosen Law Firm Announces the Filing of Securities Class Action on Behalf of Sellers of Allergan Inc. Stock From February 25, 2014 to April 21, 2014 Seeking to Recover Losses -- AGN
GlobeNewswire - Thu Dec 18, 2:59PM CST
The Rosen Law Firm, a global investor rights firm, announced today that a class action lawsuit has been filed on behalf of all sellers of Allergan Inc. stock (NYSE:AGN) between February 25, 2014 and April 21, 2014.
AGN: 210.12 (+0.95)
An Exclusive Interview With Pershing Square's William (Bill) Ackman
Matt Stewart - at Seeking Alpha - Thu Dec 18, 8:30AM CST
ZTS: 43.84 (+0.87), AGN: 210.12 (+0.95), HLF: 37.98 (+0.20), VRX: 140.33 (-0.22), HHC: 133.21 (+0.49), PAH: 23.00 (+0.01), CP: 194.85 (-0.13), APD: 148.58 (unch), BKW: 35.50 (-1.16)
Germany Bariatric Surgery Devices Market Outlook to 2020: Key players covered include Covidien, Ethicon Endosurgery and Allergan
M2 - Thu Dec 18, 5:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/mrhk9r/germany_bariatric) has announced the addition of the "Germany Bariatric Surgery Devices Market Outlook to 2020" report to their offering. Our new report, "Germany Bariatric Surgery Devices Market Outlook to 2020", provides key market data on the Germany Bariatric Surgery Devices market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Bariatric Stapling Devices, Gastric Bands and Gastric Balloons. The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Bariatric Surgery Devices market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Key Topics Covered: 1 List of Tables 2 Introduction 3 Bariatric Surgery Devices Market, Germany 4 Overview of Key Companies in Germany, Bariatric Surgery Devices Market 5 Appendix Companies Mentioned: - Covidien plc - Ethicon Endo-Surgery, Inc. - Allergan, Inc. For more information visit http://www.researchandmarkets.com/research/mr..._bariatric
AGN: 210.12 (+0.95)